Solvonis Therapeutics plc (LSE:SVNS) welcomed the Executive Order, saying the White House move is a signal that rapid-acting CNS and psychedelic-adjacent therapies are moving into the policy mainstream in the United States.
The Order directs review prioritisation, Right-to-Try access pathways, federal–state collaboration funding, data sharing and a rescheduling review following successful Phase 3 trials — steps Solvonis describes as materially relevant to the US market for novel CNS medicines.
Solvonis flagged two programmes as most immediately tied to the US shift: SVN-002, its US-focused 505(b)(2) candidate designed to bridge to an established esketamine framework; and SVN-015, which has been accepted into the US National Institute on Drug Abuse’s Addiction Treatment Discovery Program. Under the ATDP, NIDA will fund and conduct early preclinical evaluation of SVN-015, “including initial in vitro predictive safety studies, with potential progression into efficacy studies in validated preclinical models of methamphetamine and cocaine addiction if results are supportive.”
The company says the Order does not target any Solvonis programme specifically but strengthens the strategic case for its pipeline, which also includes Phase 3 asset SVN-001 for severe alcohol use disorder.
“We welcome the White House Executive Order as a major positive signal for the broader sector and as further evidence that rapid-acting CNS and psychedelic-adjacent therapies are gaining real momentum in the United States,” said Solvonis CEO Anthony Tennyson.
